Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.570 +0.050 (+1.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,417,329
Open 2.520
Bid (Size) 2.560 (2)
Ask (Size) 2.590 (11)
Prev. Close 2.520
Today's Range 2.515 - 2.615
52wk Range 1.160 - 3.400
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-11.99%
-11.99%
1 Month
+22.38%
+22.38%
3 Month
+46.02%
+46.02%
6 Month
+22.38%
+22.38%
1 Year
+108.94%
+108.94%

More News

Read More
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2024 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
Via Talk Markets
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.